603392 万泰生物
已收盘 08-21 15:00:00
资讯
新帖
简况
8月20日万泰生物涨10.00%，疫苗ETF国泰基金重仓该股
证券之星 · 08-20 16:34
8月20日万泰生物涨10.00%，疫苗ETF国泰基金重仓该股
万泰生物（603392）披露2026年半年度募集资金存放、管理与实际使用情况专项报告，8月19日股价下跌2.74%
证券之星 · 08-19 22:30
万泰生物（603392）披露2026年半年度募集资金存放、管理与实际使用情况专项报告，8月19日股价下跌2.74%
图解万泰生物中报：第二季度单季净利润同比增长6.50%
证券之星 · 08-19 18:16
图解万泰生物中报：第二季度单季净利润同比增长6.50%
万泰生物(603392.SH)发布半年度业绩，归母净亏损1.28亿元
智通财经 · 08-19 18:02
万泰生物(603392.SH)发布半年度业绩，归母净亏损1.28亿元
万泰生物(603392)6月30日股东户数4.29万户，较上期增加2.61%
证券之星 · 08-19 18:02
万泰生物(603392)6月30日股东户数4.29万户，较上期增加2.61%
每周股票复盘：万泰生物（603392）九价HPV疫苗获泰国上市许可
证券之星 · 08-16
每周股票复盘：万泰生物（603392）九价HPV疫苗获泰国上市许可
股市必读：万泰生物新发布《万泰生物关于使用部分闲置募集资金进行现金管理到期赎回并继续进行现金管理的公告》
证券之星 · 08-14
股市必读：万泰生物新发布《万泰生物关于使用部分闲置募集资金进行现金管理到期赎回并继续进行现金管理的公告》
万泰生物：若相关疫苗在有效期内正常实现销售，公司将按规定转回相应的存货跌价准备
证券之星 · 08-13
万泰生物：若相关疫苗在有效期内正常实现销售，公司将按规定转回相应的存货跌价准备
万泰生物：收取技术许可和各类销售及服务费用
证券之星 · 08-13
万泰生物：收取技术许可和各类销售及服务费用
万泰生物：公司高度重视九价HPV疫苗在9-17岁人群 "2针法"的差异化接种优势
证券之星 · 08-13
万泰生物：公司高度重视九价HPV疫苗在9-17岁人群 "2针法"的差异化接种优势
万泰生物：公司将立足主业发展，不断提升经营质量与内在价值
证券之星 · 08-13
万泰生物：公司将立足主业发展，不断提升经营质量与内在价值
万泰生物：创新疫苗商业化受多重因素影响
证券之星 · 08-13
万泰生物：创新疫苗商业化受多重因素影响
万泰生物（603392）披露使用部分闲置募集资金进行现金管理到期赎回并继续进行现金管理的公告，8月12日股价下跌0.88%
证券之星 · 08-12
万泰生物（603392）披露使用部分闲置募集资金进行现金管理到期赎回并继续进行现金管理的公告，8月12日股价下跌0.88%
万泰生物最新公告：九价HPV疫苗获泰国上市许可
证券之星 · 08-11
万泰生物最新公告：九价HPV疫苗获泰国上市许可
股市必读：万泰生物新发布《万泰生物第六届董事会第十八次会议决议公告》
证券之星 · 08-10
股市必读：万泰生物新发布《万泰生物第六届董事会第十八次会议决议公告》
每周股票复盘：万泰生物（603392）聘任新董秘及副总
证券之星 · 08-09
每周股票复盘：万泰生物（603392）聘任新董秘及副总
万泰生物（603392）披露聘任董事会秘书及副总经理公告，8月7日股价上涨4.55%
证券之星 · 08-07
万泰生物（603392）披露聘任董事会秘书及副总经理公告，8月7日股价上涨4.55%
每周股票复盘：万泰生物（603392）RSV疫苗临床试验获受理
证券之星 · 07-26
每周股票复盘：万泰生物（603392）RSV疫苗临床试验获受理
万泰生物：目前公司疫苗已在全国31个省级政府官方预约平台上线
证券日报网 · 07-23
万泰生物：目前公司疫苗已在全国31个省级政府官方预约平台上线
万泰生物（603392）新增【肝炎】概念
证券之星 · 07-22
万泰生物（603392）新增【肝炎】概念
加载更多
公司概况
公司名称：
北京万泰生物药业股份有限公司
所属行业：
医药制造业
上市日期：
2020-04-29
主营业务：
北京万泰生物药业股份有限公司的主营业务是诊断试剂、疫苗以及医疗器械的研发、生产和销售。公司的主要产品是体外诊断试剂、诊断仪器、重组戊型肝炎疫苗、二价HPV疫苗、鼻喷流感病毒载体新冠肺炎疫苗、九价HPV疫苗。
发行价格：
8.75
{"stockData":{"symbol":"603392","market":"SH","secType":"STK","nameCN":"万泰生物","latestPrice":30.59,"timestamp":1787295601000,"preClose":30.81,"halted":0,"volume":20173729,"delay":0,"changeRate":-0.0071,"floatShares":1264000000,"shares":1264000000,"eps":-0.3026,"marketStatus":"已收盘","change":-0.22,"latestTime":"08-21 15:00:00","open":30.6,"high":32.55,"low":29.96,"amount":630000000,"amplitude":0.0841,"askPrice":30.6,"askSize":29,"bidPrice":30.59,"bidSize":85,"shortable":0,"etf":0,"ttmEps":-0.3026,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787535000000},"marketStatusCode":5,"adr":0,"adjPreClose":30.81,"symbolType":"stock","openAndCloseTimeList":[[1787275800000,1787283000000],[1787288400000,1787295600000]],"highLimit":33.89,"lowLimit":27.73,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1264392804,"isCdr":false,"pbRate":3.3,"roa":"--","roe":"--","epsLYR":-0.31,"committee":0.752047,"marketValue":38678000000,"turnoverRate":0.016,"status":1,"floatMarketCap":38678000000},"requestUrl":"/m/hq/s/603392","defaultTab":"news","newsList":[{"id":"2660402106","title":"8月20日万泰生物涨10.00%，疫苗ETF国泰基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2660402106","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660402106?lang=zh_cn&edition=full","pubTime":"2026-08-20 16:34","pubTimestamp":1787214894,"startTime":"0","endTime":"0","summary":"证券之星消息，8月20日万泰生物涨10.00%，收盘报30.81元，换手率0.54%，成交量6.83万手，成交额2.09亿元。重仓万泰生物的公募基金请见下表：根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共5家，其中持有数量最多的公募基金为国泰基金的疫苗ETF国泰。疫苗ETF国泰的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000028808.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09633","BK1200","603392","LU1981816686.USD","BK1589","BK0239","159643"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660297624","title":"万泰生物（603392）披露2026年半年度募集资金存放、管理与实际使用情况专项报告，8月19日股价下跌2.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660297624","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660297624?lang=zh_cn&edition=full","pubTime":"2026-08-19 22:30","pubTimestamp":1787149829,"startTime":"0","endTime":"0","summary":"截至2026年8月19日收盘，万泰生物报收于28.01元，较前一交易日下跌2.74%，最新总市值为354.16亿元。近日，北京万泰生物药业股份有限公司披露2026年半年度募集资金存放、管理与实际使用情况。2026年上半年，公司实际投入募集资金项目7,695.77万元，截至2026年6月30日，募集资金余额为131,535.81万元，其中专户余额26,785.81万元，保本型理财产品余额104,750.00万元。公司对募集资金实行专户存储，签署三方及四方监管协议，规范使用募集资金。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900043391.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603392","BK1589","BK1200","BK0239","09633","LU1981816686.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660133444","title":"图解万泰生物中报：第二季度单季净利润同比增长6.50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660133444","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660133444?lang=zh_cn&edition=full","pubTime":"2026-08-19 18:16","pubTimestamp":1787134581,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物2026年中报显示，上半年度公司主营收入10.48亿元，同比上升24.29%；归母净利润-1.28亿元，同比上升10.92%；扣非净利润-1.69亿元，同比上升30.39%；其中2026年第二季度，公司单季度主营收入5.25亿元，同比上升18.55%；单季度归母净利润-8533.23万元，同比上升6.5%；单季度扣非净利润-1.04亿元，同比上升24.2%；负债率13.17%，投资收益3260.24万元，财务费用910.04万元，毛利率63.91%。财报数据概要请见下图:本文数据来源于万泰生物2026年中报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900031993.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603392","09633"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660441764","title":"万泰生物(603392.SH)发布半年度业绩，归母净亏损1.28亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2660441764","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660441764?lang=zh_cn&edition=full","pubTime":"2026-08-19 18:02","pubTimestamp":1787133779,"startTime":"0","endTime":"0","summary":"智通财经APP讯，万泰生物(603392.SH)披露2026年半年度报告，报告期公司实现营业收入10.48亿元，同比增长24.29%;归属于上市公司股东的净利润亏损1.28亿元，同比收窄;扣非净利润亏损1.69亿元，同比收窄;基本每股收益-0.10元。营业收入增长，主要是九价HPV疫苗上市后持续推进终端准入销售放量，疫苗板块营业收入较上年同期增加。归属于上市公司股东的净利润较上年同期亏损有所收窄，原因同上述营业收入影响因素。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1482025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["603392","BK1589","BK0239","LU1981816686.USD","BK1200","09633"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660441791","title":"万泰生物(603392)6月30日股东户数4.29万户，较上期增加2.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660441791","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660441791?lang=zh_cn&edition=full","pubTime":"2026-08-19 18:02","pubTimestamp":1787133723,"startTime":"0","endTime":"0","summary":"证券之星消息，近日万泰生物披露，截至2026年6月30日公司股东户数为4.29万户，较3月31日增加1091.0户，增幅为2.61%。在医疗器械行业个股中，万泰生物股东户数高于行业平均水平，截至6月30日，医疗器械行业平均股东户数为2.15万户。从股价来看，2026年3月31日至2026年6月30日，万泰生物区间跌幅为32.15%，在此期间股东户数增加1091.0户，增幅为2.61%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900031479.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1200","603392","LU1981816686.USD","09633","BK0239","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659175048","title":"每周股票复盘：万泰生物（603392）九价HPV疫苗获泰国上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2659175048","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659175048?lang=zh_cn&edition=full","pubTime":"2026-08-16 02:28","pubTimestamp":1786818492,"startTime":"0","endTime":"0","summary":"截至2026年8月14日收盘，万泰生物报收于30.1元，较上周的30.53元下跌1.41%。本周，万泰生物8月12日盘中最高价报31.89元。本周关注点来自公司公告汇总：九价HPV疫苗获泰国上市许可，系首个境外上市许可。公司公告汇总万泰生物关于公司九价HPV疫苗获得泰国上市许可的公告北京万泰生物药业股份有限公司全资子公司厦门万泰沧海生物技术有限公司自主研发的九价HPV疫苗获得泰国食品药品监督管理局批准，成为该产品首个境外上市许可。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081600000588.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09633","BK1200","BK1589","603392","LU1981816686.USD","159646","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659619791","title":"股市必读：万泰生物新发布《万泰生物关于使用部分闲置募集资金进行现金管理到期赎回并继续进行现金管理的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2659619791","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659619791?lang=zh_cn&edition=full","pubTime":"2026-08-14 02:08","pubTimestamp":1786644495,"startTime":"0","endTime":"0","summary":"公司公告汇总万泰生物关于使用部分闲置募集资金进行现金管理到期赎回并继续进行现金管理的公告北京万泰生物药业股份有限公司使用部分闲置募集资金35,000.00万元进行现金管理，购买民生银行和浦发银行的结构性存款产品，期限分别为364天和360天，产品均为保本浮动收益型，不影响募投项目实施。公司管理层始终高度重视全体股东利益，持续密切关注公司股价及资本市场情况。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081400001332.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603392","09633","BK1589","BK0239","BK1200","LU1981816686.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659310861","title":"万泰生物：若相关疫苗在有效期内正常实现销售，公司将按规定转回相应的存货跌价准备","url":"https://stock-news.laohu8.com/highlight/detail?id=2659310861","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659310861?lang=zh_cn&edition=full","pubTime":"2026-08-13 15:33","pubTimestamp":1786606398,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物08月13日在投资者关系平台上答复投资者关心的问题。具体计提金额及相关情况请详见公司相关信息披露。关于已计提减值存货的后续处理：若相关疫苗在有效期内正常实现销售，公司将按规定转回相应的存货跌价准备，对当期营业收入和利润均产生正向影响。公司始终严格遵守疫苗管理相关法律法规，确保每一支上市疫苗的质量安全。感谢您对公司的关注。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081300020186.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1589","603392","09633","BK1200","159646","LU1981816686.USD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659131725","title":"万泰生物：收取技术许可和各类销售及服务费用","url":"https://stock-news.laohu8.com/highlight/detail?id=2659131725","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659131725?lang=zh_cn&edition=full","pubTime":"2026-08-13 15:33","pubTimestamp":1786606395,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物08月13日在投资者关系平台上答复投资者关心的问题。贵司出口原液和标准。那么本地化生产成品疫苗后销售环节，是否也有利益分成？公司与泰国和印尼本土伙伴一起，按照已签署的合作协议，合力推进九价HPV疫苗本土化生产相关落地工作。公司依据双方的合作方式及合同约定，收取技术许可和各类销售及服务费用。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081300020183.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1589","603392","09633","BK1200","LU1981816686.USD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659131225","title":"万泰生物：公司高度重视九价HPV疫苗在9-17岁人群 \"2针法\"的差异化接种优势","url":"https://stock-news.laohu8.com/highlight/detail?id=2659131225","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659131225?lang=zh_cn&edition=full","pubTime":"2026-08-13 15:33","pubTimestamp":1786606395,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物08月13日在投资者关系平台上答复投资者关心的问题。投资者提问：国产九价HPV疫苗与进口的疫苗在14岁和17岁之间有少打一针的差异化优势，建议公司集中力量在这个年龄段搞好宣传工作，提高疫苗的普及率。公司高度重视九价HPV疫苗在9-17岁人群 \"2针法\"的差异化接种优势，正积极通过学术推广、科普教育等多种方式提升该年龄段的接种认知和普及率。公司第三代HPV疫苗临床前研究按计划有序进行中。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081300020181.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1981816686.USD","BK1589","BK0239","603392","09633","BK1200","159646"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659317981","title":"万泰生物：公司将立足主业发展，不断提升经营质量与内在价值","url":"https://stock-news.laohu8.com/highlight/detail?id=2659317981","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659317981?lang=zh_cn&edition=full","pubTime":"2026-08-13 15:33","pubTimestamp":1786606394,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物(603392)08月13日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好！巨亏的智飞生物拟斥资1.5-3亿元回购股票，体现了一种责任担当。公司管理层有何感想？万泰生物回复：您好！公司管理层始终高度重视全体股东利益，持续密切关注公司股价及资本市场情况。股份回购涉及公司资金使用、长期研发与产业布局等多重因素，需要充分论证、统筹权衡。公司将立足主业发展，不断提升经营质量与内在价值；若后续筹划相关资本运作事项，将严格按照监管规则及时履行信息披露义务。感谢您对公司的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：沈彬","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081300020180.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","09633","BK1200","603392","LU1981816686.USD","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659131226","title":"万泰生物：创新疫苗商业化受多重因素影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2659131226","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659131226?lang=zh_cn&edition=full","pubTime":"2026-08-13 15:33","pubTimestamp":1786606394,"startTime":"0","endTime":"0","summary":"创新疫苗商业化受公众认知、行业竞争、政策环境等多重因素影响，存在较大不确定性。公司戊肝疫苗属于全球首创品种，疾病认知培育周期漫长；二价 HPV 疫苗上市后市场竞争、需求格局发生超预期变化；鼻喷新冠疫苗需求受外部防疫形势影响较大。当前九价 HPV 疫苗市场竞争充分，团队充分吸取过往经验，把控产能释放节奏，加快各省准入与渠道推广，密切跟踪终端需求，多措并举推动产品放量。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081300020176.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09633","603392","BK1589","BK1200","BK0239","LU1981816686.USD","159646"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658493903","title":"万泰生物（603392）披露使用部分闲置募集资金进行现金管理到期赎回并继续进行现金管理的公告，8月12日股价下跌0.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658493903","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658493903?lang=zh_cn&edition=full","pubTime":"2026-08-12 22:10","pubTimestamp":1786543829,"startTime":"0","endTime":"0","summary":"截至2026年8月12日收盘，万泰生物报收于30.44元，较前一交易日下跌0.88%，最新总市值为384.88亿元。该股当日开盘31.5元，最高31.89元，最低30.43元，成交额达2.45亿元，换手率为0.62%。近日，万泰生物发布《关于使用部分闲置募集资金进行现金管理到期赎回并继续进行现金管理的公告》。公告显示，公司使用部分闲置募集资金35,000.00万元进行现金管理，购买民生银行和浦发银行的结构性存款产品，期限分别为364天和360天，产品均为保本浮动收益型，不影响募投项目实施。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081200040036.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1200","603392","BK0239","LU1981816686.USD","09633","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658966049","title":"万泰生物最新公告：九价HPV疫苗获泰国上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2658966049","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658966049?lang=zh_cn&edition=full","pubTime":"2026-08-11 17:26","pubTimestamp":1786440367,"startTime":"0","endTime":"0","summary":"万泰生物(603392.SH)公告称，公司全资子公司万泰沧海自主研发的九价HPV疫苗获得泰国食品药品监督管理局批准，取得首个境外上市许可。该疫苗已于2025年获国家药监局批准，为我国首款、全球第二款九价HPV疫苗，适用于9-45岁女性。本次获批标志着该产品具备出口泰国市场资质，将助力公司拓展东南亚市场，构建全球化疫苗网络。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081100027620.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09633","159646","BK1589","BK1200","BK0239","LU1981816686.USD","603392"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658429670","title":"股市必读：万泰生物新发布《万泰生物第六届董事会第十八次会议决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2658429670","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658429670?lang=zh_cn&edition=full","pubTime":"2026-08-10 01:29","pubTimestamp":1786296548,"startTime":"0","endTime":"0","summary":"万泰生物关于聘任董事会秘书及副总经理的公告陈岱具备法律职业资格及五年以上工作经验，已通过上海证券交易所董事会秘书任职培训，未持有公司股份；尚喜斌现任子公司总经理，持有公司股份10,000股；两人任职资格均符合相关法律法规要求，任期至第六届董事会届满。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081000000647.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1200","09633","BK1589","603392","LU1981816686.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658673720","title":"每周股票复盘：万泰生物（603392）聘任新董秘及副总","url":"https://stock-news.laohu8.com/highlight/detail?id=2658673720","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658673720?lang=zh_cn&edition=full","pubTime":"2026-08-09 02:05","pubTimestamp":1786212314,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘，万泰生物报收于30.53元，较上周的30.6元下跌0.23%。本周，万泰生物8月4日盘中最高价报31.26元。本周关注点公司公告汇总：万泰生物聘任陈岱为董事会秘书、尚喜斌为副总经理。万泰生物于2026年8月7日发布公告，聘任陈岱先生为公司董事会秘书，其具备法律职业资格，已通过上海证券交易所董事会秘书任职培训，未持有公司股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080900000499.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1589","09633","BK0239","603392","LU1981816686.USD","BK1200"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657373644","title":"万泰生物（603392）披露聘任董事会秘书及副总经理公告，8月7日股价上涨4.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657373644","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657373644?lang=zh_cn&edition=full","pubTime":"2026-08-07 22:18","pubTimestamp":1786112288,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘，万泰生物报收于30.53元，较前一交易日上涨4.55%，最新总市值为386.02亿元。该股当日开盘29.1元，最高30.56元，最低28.86元，成交额达2.63亿元，换手率为0.7%。近日，万泰生物披露第六届董事会第十八次会议决议公告。经董事长邱子欣先生提名，董事会同意聘任陈岱先生为公司董事会秘书，聘任尚喜斌先生为公司副总经理，任期均至第六届董事会任期届满之日止。表决结果均为同意8票、反对0票、弃权0票。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700040978.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603392","LU1981816686.USD","BK1589","BK1200","09633","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654057461","title":"每周股票复盘：万泰生物（603392）RSV疫苗临床试验获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2654057461","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654057461?lang=zh_cn&edition=full","pubTime":"2026-07-26 02:56","pubTimestamp":1785005770,"startTime":"0","endTime":"0","summary":"截至2026年7月24日收盘，万泰生物报收于28.53元，较上周的28.55元下跌0.07%。本周，万泰生物7月21日盘中最高价报29.63元。万泰生物当前最新总市值360.73亿元，在医疗器械板块市值排名4/129，在两市A股市值排名512/5200。本周关注点公司公告汇总：冻干重组RSV疫苗临床试验申请获国家药监局受理。临床前数据显示其具有良好的安全性和免疫原性。本次申请受理标志着公司重组蛋白疫苗研发取得阶段性进展，后续仍存在研发不确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072600000933.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159646","LU1981816686.USD","09633","603392","BK0239","BK1200","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653726840","title":"万泰生物：目前公司疫苗已在全国31个省级政府官方预约平台上线","url":"https://stock-news.laohu8.com/highlight/detail?id=2653726840","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653726840?lang=zh_cn&edition=full","pubTime":"2026-07-23 21:01","pubTimestamp":1784811660,"startTime":"0","endTime":"0","summary":"证券日报网讯7月23日，万泰生物在互动平台回答投资者提问时表示，目前公司疫苗已在全国31个省级政府官方预约平台上线，如北京“京通”、上海“随申办”、浙江“浙里办”等。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-07-23/doc-iniivazc5330538.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-07-23/doc-iniivazc5330538.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1589","09633","LU1981816686.USD","603392","BK1200","159646","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653750791","title":"万泰生物（603392）新增【肝炎】概念","url":"https://stock-news.laohu8.com/highlight/detail?id=2653750791","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653750791?lang=zh_cn&edition=full","pubTime":"2026-07-22 20:30","pubTimestamp":1784723417,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，7月22日万泰生物新增概念。万泰生物主营业务：体外诊断试剂、体外诊断仪器与疫苗的研发、生产及销售。万泰生物2026年一季报显示，一季度公司主营收入5.23亿元，同比上升30.63%；归母净利润-4298.38万元，同比上升18.56%；扣非净利润-6460.29万元，同比上升38.49%；负债率12.88%，投资收益1472.47万元，财务费用532.12万元，毛利率69.86%。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072200044353.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09633","BK1589","BK1200","LU1981816686.USD","BK0239","603392"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1787310115685,"stockEarnings":[{"period":"1week","weight":-0.0016},{"period":"1month","weight":0.0639},{"period":"3month","weight":-0.1593},{"period":"6month","weight":-0.2328},{"period":"1year","weight":-0.4574},{"period":"ytd","weight":-0.3144}],"compareEarnings":[{"period":"1week","weight":-0.0059},{"period":"1month","weight":0.0102},{"period":"3month","weight":-0.0509},{"period":"6month","weight":-0.0437},{"period":"1year","weight":0.0365},{"period":"ytd","weight":-0.0164}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京万泰生物药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"42923人(较上一季度增加2.61%)","perCapita":"29457股","listingDate":"2020-04-29","address":"北京市昌平区科学园路31号","registeredCapital":"126439万元","survey":" 北京万泰生物药业股份有限公司的主营业务是诊断试剂、疫苗以及医疗器械的研发、生产和销售。公司的主要产品是体外诊断试剂、诊断仪器、重组戊型肝炎疫苗、二价HPV疫苗、鼻喷流感病毒载体新冠肺炎疫苗、九价HPV疫苗。","listedPrice":8.75},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"万泰生物(603392)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供万泰生物(603392)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"万泰生物,603392,万泰生物股票,万泰生物股票老虎,万泰生物股票老虎国际,万泰生物行情,万泰生物股票行情,万泰生物股价,万泰生物股市,万泰生物股票价格,万泰生物股票交易,万泰生物股票购买,万泰生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"万泰生物(603392)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供万泰生物(603392)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}